Mike Klein, CEO, Genomenon
Michigan-based Genomenon, a genomic health IT company, has its name derived from Ancient Greek, meaning ‘born out of need’. The story behind its inception aptly justifies the name and illustrates the ‘need’ that transformed the way genetic and cancer diagnoses, treatments, and discoveries are made. During his clinical practice and genomic research, Dr. Mark Kiel often got frustrated with the time-consuming process of manual curation. It was challenging to interpret genomic data in the right context of clinical research for precision medicine due to the manual effort to search and analyze the rapidly growing medical literature for disease-related genes and variants. While experts told him that it was impossible, he was determined to find a better way and joined forces with Steve Schwartz, an expert in big data and AI. Together they founded Genomenon to keep pace with the constant scientific and medical advancements made in genomics and connect that research to patient DNA to drive diagnostic and treatment decisions for patients with rare genetic diseases and cancer.
Genomenon provides a comprehensive genomicsearch platform named Mastermind to identify and analyze genetic evidence found across the complete corpus of scientific articles. Powered by its proprietary Genomic Language Processing (GLP) algorithms and genomic literature database, Mastermind finds every published association across genes, variants, diseases, phenotypes, and therapies with a simple Google-like interface. The search results empower scientists and researchers at pharmaceutical companies, clinical labs, and universities across the globe to understand diseases at a molecular level. “We are revolutionizing the way genomic informationis searched, made available, and understood,” says Mike Klein, CEO of Genomenon.
Genomenon powers precision medicine for both clinical and pharmaceutical research.
We are revolutionizing the way genomic information is searched, made available, and understood
At the clinical level, the Mastermind Genomic Search Engine connects patients’ variants in the context of a specific disease or set of phenotypes to clinically relevant search results and provides deep insight into each article relevant to patient diagnoses. “Our computational intelligence enables users to search across the most comprehensive collection of genetic literature, 8 million full-text genomic articles and 2 million supplemental datasets, to find the answers they need,” remarks Klein.
This can reduce variant interpretation time 5-fold and increase diagnostic yield by 10-12 percent, and assures repeatability in reporting genetic testing results. Thousands of doctors in over 100 countries use Mastermind to effectively diagnose cancer patients and babies born with rare diseases.
Pharmaceutical and biopharma companies look to understand the entire genetic landscape of a disease rather than case by case. To that end, Genomenon offers the Mastermind Genomic LandscapeTM, essentially a dataset with comprehensive genetic information backed by scientific evidence to drive successful precision medicine programs. Mastermind enables target identification and validation by providing the genetic drivers for a disease and pinpointing variants known to be pathogenic. The genomic landscape is also a powerful tool for identifying the genetic biomarkers needed to screen patients for clinical trial stratification.
Genomenon has been consistently recognized as an innovator since its inception. The company was recently named the 2020 Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan for delivering comprehensive genomics data interpretation, resulting in more accurate diagnoses.
Later this year, the company will be the first to deliver a comprehensive genomic landscape for ALS (Lou Gherig’s Disease) for researchers and pharmaceutical companies focused on the disease. With its comprehensive genomics data interpretation for precision medicine, Genomenon is poised to maintain a strategic role in evolving value-based healthcare landscape, improving patient outcomes.